Bionews, Inc.

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly‘s antibody therapy donanemab, now Kisunla, for certain adults with Alzheimer’s disease. Specifically, Kisunla is indicated for patients with early symptomatic Alzheimer’s — to include individuals with mild cognitive impairment or mild dementia, and confirmed evidence of amyloid plaques, the toxic protein aggregates, or clumps, that accumulate in the brain of those with the neurodegenerative disease. https://lnkd.in/g779BTtG Part of the Bionews, Inc. portfolio, Alzheimer's News Today shares timely and trusted news, information, and patient perspectives on living with Alzheimer's disease. #Bionews #FDAApproval #EliLilly #AlzheimersNewsToday

The U.S. Food and Drug Administration (FDA) has expanded its approval of Elevidys (delandistrogene moxeparvovec-rokl), authorizing the one-time gene therapy for individuals with Duchenne muscular dystrophy (DMD) ages 4 and older regardless of their ability to walk. Previously, the treatment had been approved for DMD children ages 4 to 5 who could walk. Doug Ingram, president and CEO of Elevidys’ developer Sarepta Therapeutics, said the expanded approval “is a defining moment for the Duchenne community” as well as “a watershed occasion for the promise of gene therapy and a win for science,” in a company press release. Part of the Bionews, Inc. portfolio, Muscular Dystrophy News Today shares timely and trusted news, information, and patient perspectives on living with MD. #Bionews #RareDisease #MuscularDystrophy #FDAApproval

Chris Comish, CEO of Bionews, Inc., shares an exciting update and our unwavering commitment to the rare disease community in this must-read article. ➡️ https://lnkd.in/gnj4PMxd Learn how Bionews is: - a trusted companion for patients and caregivers - a bridge to connect patients with industry partners - creating a richer ecosystem of information, community and resources Read the full article and don't miss the latest insights from our "Living with Rare Disease" survey! ➡️ https://lnkd.in/gKri67NW #Bionews #RareDisease #ForRareByRare #RareDiseaseSurvey

Bionews New Brand Identity & Enhanced Patient Support Yesterday, Bionews, Inc. got a fresh makeover, but our commitment to the rare disease community remains stronger than ever! Read more here: https://bit.ly/4aTyDPw This isn't just about a new look (although it does look pretty awesome). It's about pushing innovation and putting patients first. We know real progress comes from meaningful #connections and authentic #conversations. What else is new at Bionews? 🔸 Industry-leading digital #engagement solutions: We've expanded our offerings to empower partners to connect with niche audiences in a trusted environment, precisely when they're making crucial healthcare decisions. 🔸 Stronger patient #support: Our commitment to patient-centricity remains at the core of everything we do. Stay tuned! We'll be sharing more exciting updates, insights and resources designed to support the rare disease community. #raredisease #Bionews #patientcentricity #digitalhealth

Bionews evolves with a bold new look! We're thrilled to share our brand refresh, and our unwavering dedication to YOU – the rare disease community and the partners who champion their voices – stands stronger than ever. Head over to our website (bionews.com) to explore the fresh look and see how Bionews, Inc. continues to be the leading source of information and connection for rare disease patients and advocates. Stay tuned for exciting updates, actionable patient insights you can use, and engaging resources specifically designed to support the rare disease community. 🚀💪💪🏽💪🏾 #Bionews #RareDisease #PatientEngagement

Mayo Clinic PaSAGE Study Team and BioNews Collaborates to Advance Rare Disease Awareness Read more here: https://lnkd.in/g9qYCiPJ The Mayo Clinic PaSAGE Study Team has announced a collaboration with BioNews Inc. to inform the future of rare disease care. This collaboration aims to understand the potential impacts of genetic therapies on patient communities and advocate for the creation and translation of patient-centered therapies. PaSAGE is funded by the National Institutes of Health to help integrate patient voices into the therapeutic research process. This collaboration will provide feedback to scientists and therapy developers about the priorities and needs of patients and families. The Mayo Clinic PaSAGE Study Team and BioNews invite stakeholders from across the rare disease community to join them in their mission to drive positive change and improve patient outcomes in the future. #Bionews #MayoClinic #RareDisease #Collaboration

🌍 Today marks #WorldMSDay, when people around the globe unite in solidarity to raise awareness of multiple sclerosis and celebrate advances in research and treatment. Organized by the MS International Federation (MSIF) the theme for 2024-2025 is diagnosis. When we raise awareness and foster understanding, we promote early diagnosis and better patient outcomes. Read more here: https://lnkd.in/gb6J_mEZ At BioNews Inc., we empower the patient and caregiver with daily news, resources, and unique patient perspectives to support each person’s unique journey, from diagnosis to disease management. Part of the BioNews portfolio, Multiple Sclerosis News Today shares timely and trusted news, information, and patient perspectives on living with MS. #BioNews #Awareness #PatientJourney #MultipleSclerosis

Mayo Clinic PaSAGE Study Team and BioNews Collaborates to Advance Rare Disease Awareness Read more here: https://lnkd.in/g9qYCiPJ The Mayo Clinic PaSAGE Study Team has announced a collaboration with BioNews Inc. to inform the future of rare disease care. This collaboration aims to understand the potential impacts of genetic therapies on patient communities and advocate for the creation and translation of patient-centered therapies. PaSAGE is funded by the National Institutes of Health to help integrate patient voices into the therapeutic research process. This collaboration will provide feedback to scientists and therapy developers about the priorities and needs of patients and families. The Mayo Clinic PaSAGE Study Team and BioNews invite stakeholders from across the rare disease community to join them in their mission to drive positive change and improve patient outcomes in the future. #Bionews #MayoClinic #RareDisease #Collaboration

Living with a rare disease can significantly impact mental health. Stress, uncertainty, and isolation, often associated with rare diseases, can take a toll on emotional well-being. In honor of Mental Health Awareness Month in May, Pulmonary Fibrosis News columnist Sam Kirton shares his experience with depression, anxiety, and a lesser-known mental health challenge, survivor’s guilt. In his recent column, Kirton shares more about survivor’s guilt: “Another form of depression, which I’ve often seen in the IPF community following a lung transplant, is referred to as survivor’s guilt. When I received my bilateral lung transplant in July 2021, I immediately realized that receiving the lungs that saved my life meant another person had died.” Read more here https://lnkd.in/dBzHSmPr Pulmonary Fibrosis News, a BioNews Inc. website, shares patient perspectives on living with pulmonary fibrosis. #BioNews #WeAreRare #RareDisease #MentalHealth

ALS News Today is proud to announce a partnership with I AM ALS to support their impactful initiatives during #ALSAwarenessMonth this May. Together, we'll be promoting the important work I AM ALS is doing to raise awareness and empower the ALS community. Mark Your Calendars! I AM ALS 2024 Community Summit: A first-of-its-kind three-day event where the ALS community can come together, share experiences, and address critical issues facing those living with ALS. (https://lnkd.in/eSE3WUn4) National Mall Flag Display: From May 29th to June 1st, the National Mall will be transformed with a sea of flags honoring those fighting ALS, both present and past. In 2022 and 2023, over 6,000 flags were displayed – a truly powerful testament to the strength of this community. I AM ALS: Founded by Brian Wallach and Sandra Abrevaya, I AM ALS is a patient-led 501(c)(3) nonprofit dedicated to providing critical support and resources to those affected by ALS. Their unwavering commitment to advocacy and raising awareness brings us one step closer to a world free of ALS. ALS News Today: Part of the BioNews portfolio, ALSNewsToday.com  shares timely and trusted news, information, and patient perspectives on living with ALS. #BioNews #RareDisease #ALSAwareness #IAMALS